Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK

Drugmaker Bristol-Myers Squibb Company (BMY) has committed $2.3 billion to a new plant in Houston, Texas, as part of a larger $40 billion U.S. investment pledge. The same day, British regulators approved Eli Lilly and Company's (LLY) weight-loss pill Foundayo for both weight management and type 2 diabetes, making the UK the first European country to do so.

The Houston facility, roughly 600,000 square feet, will produce various medicines and biologics, expected to create around 500 skilled jobs and 2,000 construction jobs between 2027 and 2030.

CEO Christopher Boerner emphasized this as a vote of confidence in America's biopharma future, aligning with an industry trend where major drugmakers, including Lilly, Johnson & Johnson, and Pfizer, are building more facilities in the U.S. due to escalating tariff pressures from the Trump administration. However, Eli Lilly opted for expansion abroad rather than inward, with Foundayo's UK approval opening a new market, even though the pill isn't yet covered by the National Health Service.

The strategy of building strength at home or chasing growth abroad remains a debate. While the Houston investment benefits Bristol-Myers Squibb, the company's best-selling drugs, Eliquis and Opdivo, are set to lose patent protection, which could impact future revenue. In the UK, Eli Lilly's Foundayo benefits from being ahead of Novo Nordisk's Wegovy and lacking NHS reimbursement, but its impact on UK sales might be modest.

Hedge fund interest in both companies varies, with Bristol-Myers Squibb gaining some support and Eli Lilly experiencing a decrease in holdings and value. Both moves demonstrate confidence but in different directions, leaving investors to weigh the long-term growth potential and short-term risks.